.png){kind=small}
Regulatory Distinction Between Cosmetic Enhancement and Drug Therapy
The global regulatory landscape in 2026, driven by the Modernization of Cosmetics Regulation Act (MoCRA) in the US and the EU Cosmetics Revision, has sharpened the distinction between "beautifying" and "treating."
The Intended Use Doctrine: A product’s classification is determined by its claims. If a body wash claims to "cleanse," it is a cosmetic; if it claims to "treat eczema," it is a drug. In 2026, regulators utilize AI to scan digital marketing and social media for "unsubstantiated medical claims," leading to immediate mandatory recalls for brands that blur these lines without proper OTC drug registration.
Safety Substantiation: Under 2026 laws, the "responsible person" for a brand must maintain digital records of safety substantiation. This includes clinical data proving that medicated actives (like salicylic acid or fluoride) are stable and non-toxic over the product’s shelf life.
Global Compliance Harmonization: Large manufacturers now design "Global Monographs," ensuring a single formulation meets the strict concentration limits of the US, EU, and China (CSAR) simultaneously, reducing the need for region-specific manufacturing.